posted on 2019-03-20, 09:57authored byUmesh T. Kadam, Isobel Roberts, Simon White, Ruth Bednall, Kamlesh Khunti, Peter M. Nilsson, Claire A. Lawson
With older and ageing populations, patients experience multiple chronic diseases at the same time. Individual chronic disease guidelines often recommend pharmacological therapies as a key intervention, resulting in patients being prescribed multiple regular medications for their different diseases. Whilst the term 'polypharmacy' has been applied to the use of multiple medications, there is no consistent definition and this term is now being used all inclusively. To improve both scientific rigor and optimal patient care, it is crucial that a standard terminology is used which reclassifies the term 'polypharmacy' into distinct phenotypes relating to the index chronic disease, additional conditions to the index ('comorbidity') or the experience of multiple chronic conditions at the same time (multimorbidity). Using three exemplar index conditions; heart failure, type 2 diabetes and breast cancer, we propose the reclassification of the term 'polypharmacy' into three distinct phenotypes. First, index drug or multi-index drug therapy, where each index condition creates multiple drug use for that condition; second, co-drug therapy, where addition of other comorbid conditions increases the multiple drug use and may influence the management of the index disease and third, multi drug therapy, where adult population with multimorbidity may be on many drugs. This paper reviews guidelines for the individual exemplars to develop the basis for the new terms and then develops the pharmaco-epidemiology of multiple drug use further by reviewing the evidence on the relationship between the phenotypic classification and important outcomes. The importance of standardising 'polypharmacy' terminology for the scientific agenda and clinical practice is that it relates to an index condition or disease safety outcomes including drug interactions, adverse side effects in hospital admissions and related 'polypill' concept.
Funding
CAL is supported by the University of Leicester Wellcome Trust Institutional Strategic Support Fund.
History
Citation
Journal of Clinical Epidemiology, 2019, 106, pp. 98-107
Author affiliation
/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Health Sciences
The file associated with this record is under embargo until 12 months after publication, in accordance with the publisher's self-archiving policy. The full text may be available through the publisher links provided above.